Cell Death and Disease (Nov 2024)

PD-L2 of tumor-derived exosomes mediates the immune escape of cancer cells via the impaired T cell function

  • Tongfeng Liu,
  • Shuwen Cheng,
  • Bo Peng,
  • Haojing Zang,
  • Xiaofeng Zhu,
  • Xuetong Wang,
  • Xujie Zhao,
  • Yinmin Gu,
  • Yongbo Pan,
  • Hongbo Hu,
  • Shan Gao

DOI
https://doi.org/10.1038/s41419-024-07191-7
Journal volume & issue
Vol. 15, no. 11
pp. 1 – 9

Abstract

Read online

Abstract The function of PD-1/PD-L1 axis have been intensively studied for immune escape of various cancers. However, the underlying function of PD-L2 remains poorly understood. Here, we demonstrate that PD-L2 is majorly expressed in exosomes with surface localization by clear cell renal cell carcinoma (ccRCC) cells. Tumor cell-derived exosome PD-L2 (TDE-PD-L2) exhibits high expression compared with TDE-PD-L1 in various cancers. In the absence of adaptive immune, TDE-PD-L2 suppresses tumor growth and metastasis. Under immune competence condition, TDE-PD-L2 is hijacked by immune cells in a PD-1-dependent manner to systematically dampen function of T cells via the increased proportion of the regulatory T cells and the decreased proportion of cytotoxic CD8+ T cells in both tumor-infiltrating T cells and spleen. The effects of TDE-PD-L2 on tumor is restored by antibodies targeting PD-L2. Collectively, we demonstrate that PD-1/TDE-PD-L2 axis systematically suppresses T cell functions, representing a potentially therapeutic strategy for ccRCC treatment.